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Abstract
Cystic fibrosis is characterized by an overly exuberant neutrophilic inflammatory
response to pathogens and other stimuli that starts very early in disease. The
overwhelming nature of this response is a primary cause of remodeling and destruction
of the airways, suggesting that anti-inflammatory therapies could be beneficial in CF.
However, finding therapies that can effectively reduce the inflammatory response
without compromising host defenses remains elusive. New approaches towards
mapping inflammatory targets promise to aid in developing novel therapeutic
strategies and improve outcomes in individuals with CF.
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1 | INTRODUCTION
Inflammation in cystic fibrosis (CF) is characterized by a marked and
persistent influx of neutrophils into the airways. Despite the
overwhelming nature of this inflammatory response, it remains
insufficient to eradicate infection, resulting in a vicious cycle of
infection, inflammation, and mucus hypersecretion/dehydration that
causes progressive remodeling and destruction of the airways. This
high degree of airway inflammation is responsible for much of the lung
disease in CF, with concentrations of inflammatory biomarkers
(particularly neutrophil elastase) the most predictive of disease
progression.1,2 Nevertheless, there are relatively few therapies
developed to directly address airway inflammation in CF. This lack
of treatment options reflects several challenges in developing effective
anti-inflammatory therapies, including difficulties in measuring airway
inflammation. This review will summarize the origins of airway
inflammation in CF, current options for treatment, and how develop-
ments in measuring biomarkers of airway inflammation may lead to a
new generation of anti-inflammatory treatments for CF.
1.1 | Origins of CF inflammation
A key finding of studies of early CF lung disease is that airway
inflammation begins at or very soon after birth. Neutrophils and
neutrophil elastase can be detected in bronchoalveolar lavage (BAL)
in patients diagnosed with CF by newborn screen as early as
3 months of age, and these inflammatory markers correlate with
future development of bronchiectasis and gas trapping on CT scan.1
This increase in inflammation does not appear to be solely a
response to infection, since less than half of infants with neutrophil
elastase detected in BAL fluid had an active pulmonary infection or
history suggesting infection. These observations suggest that
inflammation in CF airways is multifactorial (Fig. 1) and can occur
even in the absence of an infectious stimulus.
Localized hypoxia in the CF lung could explain the early
inflammation seen in the absence of obvious infection.3 The gene
mutated in CF, the cystic fibrosis transmembrane conductance
regulator (CFTR), encodes a cAMP dependent anion channel that
conducts chloride and bicarbonate and regulates the balance of
chloride secretion and sodium absorption in the airway.4 Loss of CFTR
channel activity produces a dehydrated airway surface environment
where the total mass of salt and volume of water are inadequate to
maintain mucus hydration, leading to defects in mucociliary clearance.
The resulting thickened mucus and mucus plugging in the small airway
create localized areas of hypoxia, which can trigger inflammatory
responses5 including release of cytokines such as IL-1 and activation of
the inflammatory cascade via binding to the IL-1 receptor.6 The
resultant increase in inflammation may then worsen hypoxia and
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contribute to a niche for anaerobic bacteria, thus further propagating
the inflammatory cycle.3
While infection may not be required to initiate inflammation in
CF, defects in immune responses to pathogens likely contribute to
the excessive inflammatory environment. A number of mechanisms
of immune dysregulation have been described in CF, including
aberrant responses in inflammatory cells such as neutrophils and
macrophages as well as altered signaling pathways in airway
epithelia. These aspects of immune dysregulation were reviewed
in detail in 2015 by Nichols and Chmiel in a previous volume of
“Barriers to Normalcy”7 and will be only briefly summarized here.
The mucus dehydration and impaired mucociliary clearance contrib-
ute to enhanced inflammatory responses, with failure to clear
pathogens out of the airway leading to prolonged stimulation of
inflammatory pathways.8,9 Furthermore, there is evidence that CFTR
may play a more direct role in regulation of inflammatory responses.
For example, neutrophils isolated from patients with CF tend to
undergo necrotic rather than apoptotic responses, releasing
additional pro-inflammatory molecules such as High Mobility Group
Box 1 (HMGB1) protein and metalloproteases.10,11 There is also
evidence that CFTR is involved in the acidification of phagosomes
and bacterial killing in both neutrophils and macrophages.12,13
Similarly, CF macrophages and monocytes also demonstrate defec-
tive immune response.14
Studies of animal models suggest that defects in innate immunity
contribute to the excessive inflammatory responses in CF. CF pigs
have decreased bacterial clearance and increased inflammation
relative to unaffected litter mates after exposure to bacterial
pathogens.15 CFTR knockout ferrets16 also show abnormal bacterial
clearance and enhanced inflammatory responses.17 The mechanisms
that underlie these defects are not fully defined, though there is
evidence that defective bacterial clearance in the CF pig reflects
altered airway acidification, likely related to loss of CFTR mediated
bicarbonate secretion that alters the efficacy of antimicrobial
peptides.18
Despite this evidence, the role of altered inflammatory responses
directly related to CFTR deficiency (as opposed to secondary effects
from defective mucociliary clearance) remains controversial. Systemic
infection remains uncommon in CF despite high airway bacterial
loads,19 raising some questions about the clinical relevance of
abnormalities observed in isolated CF inflammatory cells. Studies in
animal models must also be interpreted with caution, since no animal
model faithfully recapitulates all aspects of human disease. For
example, the altered airway pH observed in pigs may not be present in
humanCF,20 and airway acidification similar inmagnitude to that of the
CF pigs has been observed in asthma,21,22 a disease that is not
commonly associated with airway infection.21,22
1.2 | Anti-inflammatory therapies in CF
Although the factors that contribute to inflammation in CF are not fully
defined, the relevance of inflammation as a therapeutic target is
unquestioned.23 Nevertheless, despite intensive effort, limited thera-
pies are available. Prednisone is perhaps the most canonical anti-
inflammatory, and alternate day therapy with prednisone has been
shown to increase forced vital capacity (FVC) in treated CF patients
compared to placebo.24 However, chronic use of systemic steroids is
contraindicated due to their adverse effects including growth
retardation, osteoporosis, cataracts, hyperglycemia and risk of
opportunistic infection. High dose ibuprofen is a more targeted anti-
inflammatory that has been shown to slow the rate of decline of FEV1
in two separate double blind, placebo controlled studies,25,26 and this
clinical benefit has been associated with a decrease in neutrophil
migration to the lung.27 Although trials with ibuprofen did not show a
significant increase in adverse events between treatment and placebo
groups, the perceived risk of gastrointestinal bleeding and renal
toxicity coupledwith the need to obtain serum levels tominimize these
risks has inhibited widespread use of this drug.
The most widely used therapy in CF with anti-inflammatory
properties is azithromycin. Interest in azithromycin as a CF therapeutic
stemmed from its benefit in diffuse panbronchiolitis,28 a disease with
many similarities to CF, and was thought to possibly relate to its
antimicrobial activity against Pseudomonas aeruginosa growing in
biofilms.29 Indeed, the initial large study of chronic, low dose
azithromycin in CF was targeted towards patients with persistent
Pseudomonas infection. This study demonstrated that chronic azi-
thromycin treatment led to improvement in FEV1, a decrease in
exacerbations requiring antibiotic therapy, as well as improved quality
of life (QOL) scores.30,31 However, the clinical benefits occurred
despite minimal impact on Pseudomonas bacterial density, suggesting
that a different mechanism of action was responsible. Azithromycin
has a number of anti-inflammatory effects, including reduction in
neutrophil oxidative burst and increases neutrophil apoptosis.32,33 In
lung macrophages azithromycin also appears to inhibit apoptosis,
stimulate phagocytosis of bacteria and cellular debris, as well as skew
macrophage cytokine expression toward an anti-inflammatory phe-
notype.34 Other anti-inflammatory effects of azithromycin include
decreased mucin production with a resultant decrease in mucus
viscosity, maintenance of tight junctions between epithelial cells and
improvement of the integrity of the epithelial cell layer under
inflammatory conditions.33 These immunomodulatory effects may
FIGURE 1 Factors that contribute to the excessive inflammatory
response in CF
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underlie the benefits of azithromycin more than its anti-Pseudomonal
activity, and a largemulti-center study demonstrated clinical benefit of
chronic azithromycin in patients who did not have Pseudomonas
infection.35
Given the extensive number of pathways identified as playing
roles in CF airway inflammation, it may seem surprising that other anti-
inflammatory therapies have not yet been developed. However, an
effective anti-inflammatory for CF must manage a careful balancing
act, providing sufficient potency to reduce inflammation induced lung
damage without interfering with the ability to resolve infection. This
balance can be difficult to achieve, as revealed by the Phase II clinical
trial of BIIL 284 BS, a promising antagonist of the leukotriene B4
receptor known to play a significant role in CF airway inflammation.
This trial was stopped early due to an increase in pulmonary adverse
events in those receiving the active drug compared to placebo.36
Further studies showed that treatment of CF mice with BIIL 284 BS
interfered with their ability to resolve Pseudomonas aeruginosa
respiratory infection.37 These results showcase the difficulty of
balancing a reduction in inflammationwhile not significantly increasing
the bacterial burden with the use of anti-inflammatory therapies and
emphasize the need for pre-clinical testing of novel therapeutics.23
1.3 | Barriers to anti-inflammatory development:
Measuring airway inflammation
The dearth of effective anti-inflammatory therapies represents an
ongoing barrier to normalcy in CF and suggests a need to identify
new therapeutic targets. Testing of anti-inflammatory therapies and
other treatments in CF has become increasingly challenging, as
overall improvements in lung function and health make observing
changes in traditional endpoints such as lung function or pulmonary
exacerbations more difficult to assess without large and expensive
trials.38 However, accurately measuring airway inflammation directly
as a marker of therapeutic activity can be difficult. Indeed, most of
the major trials of anti-inflammatory therapies described above24–
26,36 did not include an airway inflammation biomarker, with the
exception of the azithromycin trial that demonstrated statistically
significant though modest changes in neutrophil elastase.30 Although
treatment related reductions in airway inflammation biomarkers were
often shown in smaller studies,27,39 better biomarkers of airway
inflammation are clearly needed to identify potential therapeutic
targets and serve as surrogate markers of efficacy for clinical trials.
This need is particularly great in young children to try and limit
inflammation before the onset of lung damage. The challenges in
developing better biomarkers reflect limitations in the primary
methods to obtain airway samples: sputum collection, bronchoal-
veolar lavage, and assessments of exhaled breath (Fig. 2 and Table 1).
1.3.1 | Sputum
Historically, assessments of airway inflammation in CF (and other
diseases) have been primarily based on analysis of biomarkers in
sputum, in part reflecting the long experience and existence of
standardized protocols for this airway sample. Given the intense
airway inflammation that characterizes CF, it is no surprise that a
multitude of inflammatory biomarkers are elevated in CF sputum, as
summarized in several excellent reviews.2,40 Among these biomarkers,
sputum neutrophil elastase has emerged as one of the most predictive,
with concentrations of sputum NE most highly correlated with lung
function decline in large studies.2,41,42
However, the utility of sputum is limited somewhat by the need for
specialized procedures to process samples that typically must be
performed immediately after collection.43Spontaneously expecto-
rated sputum likely arises from more affected regions of the lung,
and concentrations of inflammatory markers can be influenced by
regional variability in lung disease39 Furthermore, in general only older
patients with more advanced disease can regularly expectorate
sputum spontaneously. While sputum induction using hypertonic
saline can be utilized to obtain samples from patients who do not
spontaneously expectorate, many younger children have difficulty
expectorating sputum even after induction.44,45 Thus, sputum has a
limited role in assessing—and by extension treating—airway inflamma-
tion in the youngest children.
1.3.2 | Bronchoalveolar lavage fluid
For patients who cannot expectorate sputum, flexible bronchoscopy
with BAL is considered the gold standard for airway biomarker
assessment.40 Aswith sputum, numerous inflammatory biomarkers are
elevated in BAL fluid in children with CF including neutrophil counts,
neutrophil elastase, pro-inflammatory cytokines such as interleukin-8,
and others.46–51 Several of these inflammatory biomarkers correlate
with other aspects of disease severity including infection,52 radiologic
findings,51,53,54 and infant lung function testing.46,49 Like sputum,
neutrophil elastase represents one of the most informative markers in
BAL fluid, with elevated concentrations in infancy predictive of future
bronchiectasis.1,55–57
Use of BAL fluid as a source of airway inflammation biomarkers is
constrained by several limitations, including the time, expertise, and
expense needed for the procedure.58 Furthermore, bronchoscopy
requires sedation, which carries both short term risks and increasing
concerns about long term adverse outcomes.59 Due to these
limitations, BAL has seen a limited role in clinical trials, though longer
term observational studies that include BAL biomarkers such as AREST
CF have provided significant insights into early disease.51,60,61
FIGURE 2 Ease of collection and ease of biomarker
measurement (including processing steps) are generally inversely
related
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1.3.3 | Exhaled breath
Many of the limitations of sputum and BAL can be overcome through
use of exhaled breath, which contains both volatile and non-volatile
compounds that could serve as inflammatory biomarkers. Exhaled
biomarkers are often collected as exhaled breath condensate (EBC), and
since collection only requires the subject to exhale through a chilled
tube, EBC can be obtained simply and non-invasively even in young
children.62,63 Indeed, a number of airway inflammatory biomarkers that
are informative in sputum or BAL fluid are also elevated in EBC from
subjects with CF, including inflammatory cytokines,63–66 8-isopros-
tane,64,67 nitrates,64,68 leukotrienes,69 and purines,49,70 with measures
of EBC leukotrienes and purines shown to track changes related to CF
exacerbations.69,70 EBC pH has also been shown to be decreased in
subjects with CF and change with treatment of an exacerbation.71–73
With specializedmethods, EBCcanevenbecollected from theyoungest
children during infant pulmonary function testing (iPFTs).74–76
The ease of EBC collection is belied by difficulty in analysis, with
EBC being described as “easy on patients” but “hard on scientists.”77
Airway secretions in EBC arise from microaerosols generated during
respiration, which represent a very low and highly variable fraction of
the fluid volume of the condensate and may under-sample obstructed
airways.78,79 Therefore, extremely sensitive methods are typically
needed to assess the low concentrations of most traditional
biomarkers found in EBC, which ideally should also include a means
to control for variable dilution.78,80 Our own approach has been to
utilize mass spectrometry to measure relevant biomarkers as well as
urea as a dilution marker,81–83 though there are other valid
methods.30,32 Failure to adequately address these challenges impacts
the reproducibility and validity of EBC biomarkers and may limit their
utility as effective measures of airway inflammation.84
Some of the limitations of EBC can be addressed by a focus on
volatile biomarkers, which are not dependent on microaerosol
generation for incorporation in exhaled breath. Several studies had
shown that volatile organic carbon (VOC) profiles are altered in
individuals with CF and could serve as inflammatory biomarkers.85,86
One of the potentially exciting application of VOC profiling in CF is
the development of electronic “nose” systems that could provide
information on airway inflammation at the point of care.87,88
However, current methods require sophisticated mathematical
modeling to identify complex patterns in the detected VOCs, and
the reproducibility of these signatures and their relationships to
specific aspects of airway inflammation have not been established.
1.3.4 | Non airway samples
The high levels of inflammation in the airways of individuals with CF
translate into increases in systemic inflammatory biomarkers that
could be assessed in serum or plasma, which are relatively easily
obtained and analyze. Indeed, a large number of blood inflammatory
markers are elevated relative in CF, including C-reactive protein,89–92
immunoglobulin G,90,93,94 cytokines,91 tumor necrosis factor,95 and
transforming growth factor β,96 many of which are altered with
pulmonary exacerbation.91,92,96,97 However, the potential contribu-
tion of non-pulmonary inflammation reduces the specificity of these
biomarker for lung disease and limits applicability. There have also
been small trials investigating the use of biomarkers in both saliva and
urine as a surrogate for lung inflammation.98,99
1.3.5 | Imaging
A number of small studies have been done using fluorodeoxyglucose
(FDG) PET to quantify lung inflammation and follow response to
treatment of CF exacerbations. FDG is concentrated in activated
neutrophils which are recruited to sites of inflammation. The degree of
inflammation can be estimated by the degree of FDG emission. A study
following the kinetics of FDG movement to the lung showed that
increased influx into the lung correlated with a more rapid decline in
FEV1over time.100Other studies have used FDGPETmonitor changes
in inflammation during antibiotic treatment of CF exacerbation.
Patients underwent FDG PET on days 1 and 14 of treatment and
degree of inflammation was determined using standard uptake values
(SUV). This group found that over the course of 14 days of IV therapy
the max SUV decreased.101 Regular use of FDG PET CT is limited by
radiation exposure, however, as low dose CT protocols improve this
may become a useful technique to follow lung inflammation.
1.4 | Novel strategies
Despite all we have learned about the inflammatory pathways involved
in CF lung disease, numerous challenges remain in translating these
TABLE 1 Comparison of airway samples for biomarker measurement
Advantages Disadvantages Region sampled Inflammatory biomarkers
Sputum Well established
Non-invasive
Requires immediate processing
Difficult in young children
Most affected large airways Cell counts
Cytokines/proteins
Metabolites
BAL Can be used in all
subjects
Higher risk (anesthesia)
Expensive
Targeted smaller airways Cell counts
Cytokines/proteins
Metabolites
EBC Simple to collect
Non-invasive
Very low and variable biomarker
concentrations
Small airways (may under-sample
plugged airways)
Cytokines/proteins
Metabolites
S24 | GIDDINGS AND ESTHER
findings into effective anti-inflammatories. Many signaling pathways
are not easily amenable to pharmacological inhibition, often requiring
biologic antibody based treatments that while effective can be
expensive and difficult to administer.102 Other pathways may be too
vital to host defenses to serve as a viable therapeutic targets, as
suggested by the outcomes of the BIIL 284 BS study.36 Therefore,
there remains an urgent need to identify new pathways that could
serve as viable targets for anti-inflammatory development. The ideal
pathway would have defined characteristics, including an involvement
in early disease, a readily measurable biomarker of activity, and
availability of a relatively simple pharmaceutical treatment. Perhaps
most importantly, blockade of this pathway should reduce inflamma-
tion without interfering with the ability to resolve infection (Table 2).
Use of ‘omics strategies, particularly metabolomics, is well suited
towards identifying pathways that meet these criteria. The changes in
metabolite patterns associated with disease reflect cellular enzymatic
activities, which are attractive as therapeutic targets since they can
often be inhibited by small molecule therapeutics.103 Furthermore, the
identified metabolites can serve as biomarkers of pathway activity and
drug effects, many of which can be readily measured using standard
methods even in non-invasive sample such as EBC.81,82,104 The
potential metabolomics has been demonstrated in several studies that
find CF specific metabolite patterns in sputum,105 BALF,106–108
blood,109,110 and even EBC.111,112
Metabolomics studies canbeparticularly informativewhen interpreted
in conjunctionwithother ‘omicsevaluations. Forexample, oneof the largest
genewide association studies to date in CF identified associations between
disease severity and expression of the gene APIP,113 which encodes an
enzyme involved in the methionine salvage pathway, and metabolites
associated with this pathway, including polyamines and free adenine, are
associated with neutrophilic inflammation in CF.107,108,114 Similarly, the
lysophosphatidic acid receptor LPAR6has been linked toCF lungdisease in
genomic studies,115 while the lysophospholipid substrates of this receptor
are elevated in CF bronchitis.107,116 While such studies demonstrate the
promise of metabolomics to identify biomarkers and therapeutic targets,
further study is needed before the potential of these identified pathways is
truly known.
2 | CONCLUSIONS
The intense inflammation present in the airways of individuals with CF
is one of the most significant causes of progressive lung disease. Until
we have a cure for CF, development of effective anti-inflammatories
needs to be a priority for the CF research community. New approaches
using metabolomics and other strategies to map the inflammatory
targets in CF hold promise in development of new therapies.
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